Real-time Estimate
Cboe BZX
02:44:38 2024-05-01 pm EDT
|
5-day change
|
1st Jan Change
|
3.235
USD
|
+4.35%
|
|
-1.82%
|
-22.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
27.1
|
134.2
|
286.2
|
44.56
|
106
|
118.6
|
-
|
-
|
Enterprise Value (EV)
1 |
27.1
|
134.2
|
286.2
|
44.56
|
106
|
118.6
|
118.6
|
118.6
|
P/E ratio
|
-0.76
x
|
-3.57
x
|
-6.89
x
|
-0.94
x
|
-1.04
x
|
-1.38
x
|
-2.08
x
|
-2.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
89.5
x
|
191
x
|
-
|
-
|
-
|
4.59
x
|
2.18
x
|
EV / Revenue
|
-
|
89.5
x
|
191
x
|
-
|
-
|
-
|
4.59
x
|
2.18
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1
x
|
-5.17
x
|
-8.14
x
|
-0.91
x
|
-2.42
x
|
-2.12
x
|
-1.72
x
|
-1.48
x
|
FCF Yield
|
-99.6%
|
-19.3%
|
-12.3%
|
-110%
|
-41.3%
|
-47.2%
|
-58.2%
|
-67.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,419
|
5,966
|
8,832
|
9,902
|
25,565
|
38,264
|
-
|
-
|
Reference price
2 |
11.20
|
22.50
|
32.40
|
4.500
|
4.145
|
3.100
|
3.100
|
3.100
|
Announcement Date
|
3/16/20
|
3/12/21
|
3/11/22
|
3/24/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.5
|
1.5
|
-
|
-
|
-
|
25.86
|
54.54
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-33.45
|
-28.54
|
-41.43
|
-56.76
|
-87.04
|
-71.2
|
-71.11
|
-63.32
|
Operating Margin
|
-
|
-1,902.6%
|
-2,761.73%
|
-
|
-
|
-
|
-274.92%
|
-116.1%
|
Earnings before Tax (EBT)
1 |
-32.9
|
-27.52
|
-40.61
|
-54.45
|
-81.41
|
-69.76
|
-69.21
|
-62.65
|
Net income
1 |
-33.26
|
-37.59
|
-40.59
|
-54.6
|
-81.41
|
-69.76
|
-69.21
|
-62.65
|
Net margin
|
-
|
-2,505.87%
|
-2,705.8%
|
-
|
-
|
-
|
-267.58%
|
-114.87%
|
EPS
2 |
-14.70
|
-6.300
|
-4.700
|
-4.800
|
-3.980
|
-2.252
|
-1.490
|
-1.260
|
Free Cash Flow
1 |
-27
|
-25.96
|
-35.16
|
-49.04
|
-43.75
|
-56
|
-69
|
-80
|
FCF margin
|
-
|
-1,730.47%
|
-2,343.8%
|
-
|
-
|
-
|
-266.78%
|
-146.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/12/21
|
3/11/22
|
3/24/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.375
|
0.375
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.14
|
-10.49
|
-10.63
|
-16.9
|
-15.29
|
-13.94
|
-42.73
|
-14.66
|
-14.83
|
-14.82
|
-16.13
|
-17.2
|
-18.3
|
-19.57
|
-18.34
|
Operating Margin
|
-3,237.33%
|
-2,796.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.14
|
-10.81
|
-10.38
|
-17.02
|
-15.09
|
-11.96
|
-41.86
|
-13.39
|
-13.7
|
-12.46
|
-15.69
|
-16.84
|
-18.03
|
-19.2
|
-17.22
|
Net income
1 |
-11.14
|
-10.79
|
-10.38
|
-17.02
|
-15.09
|
-12.1
|
-41.86
|
-13.39
|
-13.7
|
-12.46
|
-15.69
|
-16.84
|
-18.03
|
-19.2
|
-17.22
|
Net margin
|
-2,970.4%
|
-2,876.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.400
|
-0.8000
|
-0.9000
|
-1.500
|
-1.300
|
-1.000
|
-3.200
|
-0.9100
|
-0.5100
|
-0.2000
|
-0.5850
|
-0.6175
|
-0.6175
|
-0.4875
|
-0.3950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/11/22
|
5/13/22
|
8/12/22
|
11/14/22
|
3/24/23
|
5/15/23
|
8/14/23
|
11/13/23
|
3/18/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-27
|
-26
|
-35.2
|
-49
|
-43.8
|
-56
|
-69
|
-80
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/12/21
|
3/11/22
|
3/24/23
|
3/18/24
|
-
|
-
|
-
|
Average target price
11.75
USD Spread / Average Target +279.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.07% | 79.37M | | -1.63% | 102B | | +2.55% | 96.09B | | +2.13% | 22.28B | | -16.49% | 21.4B | | -8.79% | 18.14B | | -39.98% | 17.02B | | -14.14% | 16.09B | | +5.93% | 13.83B | | +33.38% | 11.97B |
Bio Therapeutic Drugs
|